Synergistically Active and Safe Fixed Dose Combination of Meropenem and Sulbactam

Authors

  • Vijender Singh Beniwal Health Biotech Research Centre, Nalagarh Road, Baddi (HP) INDIA
  • Parmjit Arora Health Biotech Research Centre, Nalagarh Road, Baddi (HP) INDIA

DOI:

https://doi.org/10.5195/iioablett.2012.6

Keywords:

Meropenem resistance, β-lactamase inhibitors, meropenem toxicity

Abstract

Meropenem is a third generation broad spectrum antibiotic. Emergence of meropenem resistance has been reported due to development of mutant plasmid mediated metallo-β-lactamases (IMP-6) and AmpC β–lactamases. Sulbactam, a stable β-lactamase inhibitor, increase antimicrobial activity of meropenem by inhibiting the enzyme β-lactamase. Fixed dose combination of Meropenem-sulbactam in the proportion of 1:1, 1:2, 1:3, 2:1 and 3:1 were evaluated for the antimicrobial activity. Combination of meropenem and sulbactam in the ratio of 2:1 exhibited the synergistic activity. This combination was checked for the subchronic toxicity on wistar rats and no change in biochemical and physiological parameters was observed.

Author Biographies

Vijender Singh Beniwal, Health Biotech Research Centre, Nalagarh Road, Baddi (HP) INDIA

Senior Scientist,

Research and development

Parmjit Arora, Health Biotech Research Centre, Nalagarh Road, Baddi (HP) INDIA

CMD

References

Bharadwaj R, Dewan V and Pal A. An in vitro study to evaluate the synergistic activity of Norfloxacin and metronidazole. Indian J Pharmacol 2003; 35: 220-226.

Cécile A, Poirel L, Ronald JA and Nordmann P. Carbapenemase-producing Enterobacteriaceae in U. S. Rivers. Emerging Infectious Diseases (www.cdc.gov/eid) 2005; 11:2.

Hernández JR, Velasco C, Romero L, Martiìnez ML and Pascual A. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumonia isolated in Spain. Int J Antimicrob Agents 2006; 28:457-459.

Hsu HL, Lu CY, Tseng HY, Lee PI, Lai HP, Lin WC, et al., Empirical monotherapy with meropenem in serious bacterial infections in children. Microbiol Immunol Infect 2001; 34: 275-280.

Huizinga WKJ, Warren BL, Baker LW, Valleur P, Pezet DM, Hoogkamp KJA, et al., Antibiotic monotherapy with meropenem in the surgical management of intraabdominal infections. J Antimicrob Chemother 1995; 36: 179-189.

Laure M, Guillou J, Kemp M, Cavallo JD, Chomara M, Dubreuil L et al., comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infectious Dis 2010; 10:72-76.

Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis 2005;37(3):195-9.

Lim VK and Cheong YM. In-vitro activity of cefoperazone-sulbactam combination against cefoperazone resistant clinical isolates in a Malaysian general hospital., Malays J Pathol 1995; 17: 73-6.

Masuda N and Ohya S. Cross-Resistance to Meropenem, Cephems, and Quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 1847-1851.

Mouton YJ and Beuscart C. Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicob Chemother 1995; 36: 145-156.

Nordmann P and Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8:321–331.

Pfaller MA and Ronald NJ. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. J Antimicrobial ChemothL 2000; 46: 25-37.

Ryoo NH, Lee K, Limb JB, Lee YH, Baed K and Jeongb SH. Outbreak by meropenem-resistant Pseudomonas aeruginosa producing IMP-6 metallo-β-lactamase in a Korean hospital., Diagnostic Microbiology and Infectious Disease 2009; 63: 115–117.

Sinha M and Srinivasa H. Mechanisms of resistance to carbapenems in meropenem- resistant Acinetobacter isolates from clinical samples. Indian J Med Microbiol 2010; 25:121-125.

Wise R, Andrews JM, and Bedford KA. Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother 1980; 6:197-206.

Yano H, Kuga A, Okamoto R, Kitasato H, Kobayashi T and Inoue M. Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother 2001; 45: 1343–1348.

Downloads

Published

2013-01-16

Issue

Vol. 2 No. 1 (2012)

Section

Articles

License


Authors who publish with this journal agree to the following terms:

    1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.

    2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.

    3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons 3.0 License (Attribution-Noncommercial-No Derivative Works), or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
      1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
      2. Noncommercial—other users (including Publisher) may not use this Work for commercial purposes;
      3. No Derivative Works—other users (including Publisher) may not alter, transform, or build upon this Work,with the understanding that any of the above conditions can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.

    4. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.

    5. Authors are permitted and encouraged to post online a pre-publication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access). Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.

    6. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.

    7. The Author represents and warrants that:

      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.

  1. The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.